The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.
User shared progress pictures after 2 months of using 5% topical minoxidil, microneedling, and recently adding 0.01% topical finasteride. The minoxidil solution also contains caffeine, azelaic acid, retinol, adenosine, biotin, and niacinamide.
The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841. It also references Epibiotech's hair multiplication and cell therapy as potential solutions.
The user reports that using topical Dutasteride has stopped their hair loss, and they are curious about potential side effects and regrowth. They also mention having scalp psoriasis and past SSRI use affecting libido.
The user has been microneedling for 4 weeks and using treatments like minoxidil and eclipta alba oil, seeing positive but slow results. They are considering peppermint oil as a potentially more effective alternative to minoxidil.
A user shared 4-month progress pictures using a daily Hims fin/min/ketoconazole/biotin hybrid spray for hair loss, reporting positive results. Suggestions included adding microneedling to the routine.
A user shared progress pictures after using a topical solution containing Minoxidil 5%, Tretinoin, and Azelaic acid for two months. The conversation discusses the effectiveness of this treatment for hair loss.
The conversation discusses impressive results from a 28-day application of a hair loss treatment. Users compare it to their experiences with Minoxidil and Dutasteride, noting excitement over the new findings.
Verteporfin might be a potential cure for hair loss and could heal scars, which may lead to natural-looking results when combined with hairline lowering surgery. One person suggests waiting to see if verteporfin actually works as claimed.